Descriptions

The autoinhibited protein was predicted that may have potential autoinhibitory elements via cis-regPred.

Autoinhibitory domains (AIDs)

Target domain

Relief mechanism

Assay

cis-regPred

Accessory elements

No accessory elements

Autoinhibited structure

Activated structure

1 structures for P06623

Entry ID Method Resolution Chain Position Source
AF-P06623-F1 Predicted AlphaFoldDB

129 variants for P06623

Variant ID(s) Position Change Description Diseaes Association Provenance
rs436584272 2 S>A No EVA
rs456769566 3 S>A No EVA
rs476664095 4 S>A No EVA
rs438926253 16 F>Y No EVA
rs458852924 17 L>R No EVA
rs876163906 21 E>G No EVA
rs472648952 21 E>Q No EVA
rs876394141 22 T>P No EVA
rs876454362 23 V>G No EVA
rs441224095 25 T>P No EVA
rs480365492 28 E>D No EVA
rs448985271 36 R>G No EVA
rs462591773 40 G>R No EVA
rs444945721 42 G>A No EVA
rs482498595 42 G>R No EVA
rs465061358 46 L>Q No EVA
rs465061358 46 L>R No EVA
rs447244693 48 R>W No EVA
rs436698912 50 I>F No EVA
rs456683429 51 V>M No EVA
rs476820140 54 Y>H No EVA
rs432440129 54 Y>S No EVA
rs441191988 58 T>A No EVA
rs441191988 58 T>P No EVA
rs461345810 58 T>S No EVA
rs473862230 60 M>T No EVA
rs442700888 61 V>A No EVA
rs462551154 63 A>P No EVA
rs482611683 64 D>G No EVA
rs458645949 65 S>C No EVA
rs478789788 66 Y>H No EVA
rs447196087 68 I>L No EVA
rs481686404 69 T>I No EVA
rs467371743 69 T>P No EVA
rs470515810 76 F>Y No EVA
rs466272966 84 D>A No EVA
rs452667563 84 D>Y No EVA
rs454728615 85 E>K No EVA
rs474828075 87 L>R No EVA
rs443625435 94 D>H No EVA
rs438575377 100 L>R No EVA
rs458689563 108 E>K No EVA
rs440916423 111 E>G No EVA
rs478707941 111 E>Q No EVA
rs460907599 112 Q>E No EVA
rs480997894 113 L>V No EVA
rs449732315 115 E>* No EVA
rs477794721 116 L>V No EVA
rs466325343 117 A>G No EVA
rs446182844 117 A>T No EVA
rs468538793 118 D>A No EVA
rs468538793 118 D>G No EVA
rs454862988 118 D>Y No EVA
rs437158025 119 Q>P No EVA
rs452256301 120 Y>* No EVA
rs476504386 120 Y>D No EVA
rs438690474 120 Y>S No EVA
rs472394583 121 Q>H No EVA
rs441076396 122 Y>D No EVA
rs441076396 122 Y>H No EVA
rs461021843 123 Q>P No EVA
rs461021843 123 Q>R No EVA
rs481159647 124 V>G No EVA
rs443234563 125 V>A No EVA
rs443234563 125 V>G No EVA
rs463359377 126 L>V No EVA
rs477692756 127 V>G No EVA
rs446328163 128 E>A No EVA
rs446328163 128 E>G No EVA
rs460087569 129 P>A No EVA
rs480049490 130 K>Q No EVA
rs437272050 133 W>G No EVA
rs437272050 133 W>R No EVA
rs450754668 133 W>S No EVA
rs464548286 136 D>G No EVA
rs472560894 145 Q>R No EVA
rs434560780 146 W>G No EVA
rs454760130 147 Q>* No EVA
rs443347083 147 Q>H No EVA
rs474658168 147 Q>R No EVA
rs463335862 149 S>T No EVA
rs459995108 158 P>A No EVA
rs479960369 161 E>V No EVA
rs448554819 167 L>F No EVA
rs471481287 168 Y>* No EVA
rs462188559 172 F>L No EVA
rs482098385 173 L>R No EVA
rs464698970 175 K>N No EVA
rs446884664 181 L>V No EVA
rs466013946 190 E>D No EVA
rs381796648 196 K>R No EVA
rs454676061 201 E>G No EVA
rs472102371 207 S>F No EVA
rs477195657 213 E>A No EVA
rs454332554 230 H>Q No EVA
rs474248656 240 K>N No EVA
rs445335651 247 Y>N No EVA
rs442967094 248 A>G No EVA
rs462921826 249 Q>H No EVA
rs476629043 251 D>G No EVA
rs448242108 252 V>A No EVA
rs448242108 252 V>G No EVA
rs468419059 253 V>M No EVA
rs437014798 257 Y>C No EVA
rs450543344 264 T>P No EVA
rs464272380 265 I>T No EVA
rs452800721 269 F>S No EVA
rs435875566 274 T>R No EVA
rs476031666 286 L>R No EVA
rs458240288 291 N>K No EVA
rs440392353 295 K>M No EVA
rs479679595 300 D>E No EVA
rs462048579 306 S>R No EVA
rs482066595 311 T>A No EVA
rs482066595 311 T>P No EVA
rs450640491 314 C>G No EVA
rs464052878 315 A>E No EVA
rs135658705 321 V>G No EVA
rs432851321 343 V>G No EVA
rs446376216 344 G>A No EVA
rs435187305 345 E>D No EVA
rs476150056 361 L>R No EVA
rs438176636 364 A>D No EVA
rs432588206 389 R>H No EVA
rs440563025 389 R>S No EVA
rs462048043 394 F>L No EVA
rs442842828 394 F>S No EVA
rs450621237 398 T>P No EVA
rs457803450 399 I>N No EVA

No associated diseases with P06623

1 regional properties for P06623

Type Name Position InterPro Accession
domain Cyclic nucleotide phosphodiesterase, catalytic domain 165 - 399 IPR047325

Functions

Description
EC Number 3.1.4.37 Phosphoric diester hydrolases
Subcellular Localization
  • Membrane ; Lipid-anchor
  • Melanosome
  • Firmly bound to membrane structures of brain white matter
PANTHER Family
PANTHER Subfamily
PANTHER Protein Class
PANTHER Pathway Category No pathway information available

5 GO annotations of cellular component

Name Definition
cytoplasm The contents of a cell excluding the plasma membrane and nucleus, but including other subcellular structures.
extracellular space That part of a multicellular organism outside the cells proper, usually taken to be outside the plasma membranes, and occupied by fluid.
melanosome A tissue-specific, membrane-bounded cytoplasmic organelle within which melanin pigments are synthesized and stored. Melanosomes are synthesized in melanocyte cells.
myelin sheath An electrically insulating fatty layer that surrounds the axons of many neurons. It is an outgrowth of glial cells: Schwann cells supply the myelin for peripheral neurons while oligodendrocytes supply it to those of the central nervous system.
plasma membrane The membrane surrounding a cell that separates the cell from its external environment. It consists of a phospholipid bilayer and associated proteins.

2 GO annotations of molecular function

Name Definition
2',3'-cyclic-nucleotide 3'-phosphodiesterase activity Catalysis of the reaction: nucleoside 2',3'-cyclic phosphate + H2O = nucleoside 2'-phosphate.
RNA binding Binding to an RNA molecule or a portion thereof.

5 GO annotations of biological process

Name Definition
adult locomotory behavior Locomotory behavior in a fully developed and mature organism.
axonogenesis De novo generation of a long process of a neuron, including the terminal branched region. Refers to the morphogenesis or creation of shape or form of the developing axon, which carries efferent (outgoing) action potentials from the cell body towards target cells.
cyclic nucleotide catabolic process The chemical reactions and pathways resulting in the breakdown of a cyclic nucleotide, a nucleotide in which the phosphate group is in diester linkage to two positions on the sugar residue.
oligodendrocyte differentiation The process in which a relatively unspecialized cell acquires the specialized features of an oligodendrocyte. An oligodendrocyte is a type of glial cell involved in myelinating the axons of neurons in the central nervous system.
response to toxic substance Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a toxic stimulus.

4 homologous proteins in AiPD

UniProt AC Gene Name Protein Name Species Evidence Code
Q92802 N4BP2L2 NEDD4-binding protein 2-like 2 Homo sapiens (Human) PR
P09543 CNP 2',3'-cyclic-nucleotide 3'-phosphodiesterase Homo sapiens (Human) PR
P16330 Cnp 2',3'-cyclic-nucleotide 3'-phosphodiesterase Mus musculus (Mouse) PR
P13233 Cnp 2',3'-cyclic-nucleotide 3'-phosphodiesterase Rattus norvegicus (Rat) PR
10 20 30 40 50 60
MSSSGAKDKP ELQFPFLQDE ETVATLQECK TLFILRGLPG SGKSTLARFI VDKYRDGTKM
70 80 90 100 110 120
VSADSYKITP GARGSFSEEY KQLDEDLAAC CRRDFRVLVL DDTNHERERL EQLFELADQY
130 140 150 160 170 180
QYQVVLVEPK TAWRLDCAQL KEKNQWQLSA DDLKKLKPGL EKDFLPLYFG WFLTKKSSAA
190 200 210 220 230 240
LWKTGQTFLE ELGNHKAFKK ELRHFVSGDE PREKIELVTY FGKRPPGVLH CTTKFCDYGK
250 260 270 280 290 300
AAGAEEYAQQ DVVKKSYCKA FTLTISALFV TPKTTGARVE LSEQQLALWP NDVDKLSPSD
310 320 330 340 350 360
NLPRGSRAHI TLGCAGDVEA VQTGIDLLEI VRQEKGGSRG EEVGELSRGK LYSLGSGRWM
370 380 390
LSLAKKMEVR AIFTGYYGKG KAVPIRSGRK GGSFQSCTII